What it sells
A platform to make artificial viruses as cancer therapeutics.
Business model breakdown
Workflow: what inputs become what output?
Computer-aided design of oncolytic RNA viruses, synthetic DNA assembly and testing; lead candidate entering cGMP manufacturing with Genezen (Nov 2025).
Economics: what it saves and how it charges
UnverifiedPre-revenue therapeutics developer; value from advancing candidates (partnerships/financing); no pricing.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.